中草药

萜类成分抗肝纤维化作用及其机制研究进展

PDF下载

杨建展, 吴烦, 沈东宁, 扶婷, 刘博, 徐方方

中草药 | 中药防治器官纤维化研究 2026,57(18): 7110-7123

收起

中草药 |中药防治器官纤维化研究 2026 , 57 (18) : 7110 -7123

萜类成分抗肝纤维化作用及其机制研究进展

全屏

杨建展, 吴烦, 沈东宁, 扶婷, 刘博, 徐方方

作者信息

通讯作者:

徐方方

作者简介:

杨建展: 杨建展，男，硕士研究生，研究方向为中药抗肝纤维化。E-mail:Ysngzza@163.com

Advances on effects of terpenoids against hepatic fibrosis and their mechanisms

YANG Jianzhan, WU Fan, SHEN Dongning, FU Ting, LIU Bo, XU Fangfang

Affiliations

doi: 10.7501/j.issn.0253-2670.2026.18.004

文章导航

摘要

收起

肝纤维化是肝脏在慢性损伤后自我修复过程中细胞外基质异常沉淀的结果，持续性肝纤维化会发展为肝硬化、肝癌等恶性疾病。肝纤维化目前没有特效治疗药物，因此，早期预防和干预对于延缓疾病进展、降低重症肝病的发病率具有重要意义。近年来，萜类成分因其显著的多靶点、多通路抗肝纤维化作用而成为研究热点，其作用机制与抗炎、抗氧化应激、抗凋亡、调节细胞外基质沉淀降解等有关。通过系统综述近年国内外文献报道的具有抗肝纤维化活性的天然萜类成分，对其化学结构及分子机制进行归纳分析，为萜类抗肝纤维化创新药物的研发提供理论依据和研究思路。

关键词

肝纤维化 / 天然药物 / 齐墩果酸 / TGF/Smad信号通路 / Nrf2/HO-1信号通路

Abstract

收起

Hepatic fibrosis is the pathological consequence of abnormal extracellular matrix deposition in the liver during the self-repair process following chronic injury. Persistent hepatic fibrosis can progress to malignant conditions such as cirrhosis and liver cancer. Currently, no specific therapeutic drugs exist for hepatic fibrosis, therefore, early prevention and intervention are of great significance for delaying disease progression and reducing the incidence of severe liver diseases. In recent years, terpenoids have emerged as a research hotspot due to their significant multi-target and multi-pathway anti-hepatic fibrosis effects. Their mechanisms are associated with anti-inflammation, antioxidative stress, anti-apoptosis, and the regulation of extracellular matrix deposition and degradation. This article systematically reviews natural terpenoids with anti-hepatic fibrosis activity reported in domestic and international literature in recent years, and summarizes their chemical structures and molecular mechanisms, providing a theoretical basis and research perspectives for the research and development of innovative anti-hepatic fibrosis drugs derived from terpenoids.

Key words

hepatic fibrosis / natural drugs / oleanlic acid / TGF/Smad pathway / Nrf2/HO-1 pathway

引用本文

杨建展, 吴烦, 沈东宁, 扶婷, 刘博, 徐方方. 萜类成分抗肝纤维化作用及其机制研究进展. 中草药, 2026 , 57 (18) : 7110 -7123 . DOI: 10.7501/j.issn.0253-2670.2026.18.004

YANG Jianzhan, WU Fan, SHEN Dongning, FU Ting, LIU Bo, XU Fangfang. Advances on effects of terpenoids against hepatic fibrosis and their mechanisms[J]. Chinese Traditional and Herbal Drugs, 2026 , 57 (18) : 7110 -7123 . DOI: 10.7501/j.issn.0253-2670.2026.18.004

基金

收起

广东省科技计划项目 (2023B1212060062,2023B1212060063); 广州市科技局项目 (2024A04J9997,2025A03J4085)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

Younossi Z M, Loomba R, Anstee Q M, et al. Diagnostic modalities for nonalcoholic fatty liver disease,nonalcoholic steatohepatitis, and associated fibrosis[J]. Hepatology, 2018, 68(1):349-360.
潘圆未,平键,徐列明.诱导活化肝星状细胞凋亡主要信号通路的研究进展[J]. 临床肝胆病杂志, 2014,30(2):182-185.
Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3):151-166.
Omata M, Cheng A L, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma:A 2017 update[J]. Hepatol Int,2017, 11(4):317-370.
Huang Y, Deng X, Liang J. Modulation of hepatic stellate cells and reversibility of hepatic fibrosis[J]. Exp Cell Res,2017, 352(2):420-426.
辛晟梁,徐小元. 2024年肝纤维化、肝硬化及门静脉高压临床研究进展[J]. 中华肝脏病杂志, 2025, 33(1):7-9.
肖滢,吴治念,鲁洁,等.代谢重编程介导的肝星状细胞活化在肝纤维化发生机制中的作用[J]. 中华肝脏病杂志, 2024, 32(11):1053-1056.
牛丽娜,窦婧,李栋栋,等.细胞凋亡在肝纤维化发生、发展中的作用研究进展[J]. 肝脏, 2023, 28(11):1369-1372.
Perel P, Roberts I, Sena E, et al. Comparison of treatment effects between animal experiments and clinical trials:Systematic review[J]. BMJ, 2007, 334(7586):197.
Roehlen N, Crouchet E, Baumert T F. Liver fibrosis:Mechanistic concepts and therapeutic perspectives[J]. Cells, 2020, 9(4):875.
Liu Z S, Wei S, Jiang Y, et al. Protein phosphatase 6regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway[J]. J Hepatol, 2025, 83(3):630-642.
Newman D J, Cragg G M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to09/2019[J]. J Nat Prod, 2020, 83(3):770-803.
苏雯清,杨晓男,梁凌玲,等.萜类化学成分的药理作用研究进展[J]. 右江民族医学院学报, 2025, 47(4):678-683.
李娇妹,郑纺,翟丽娟,等.三萜类化合物抗肿瘤活性研究进展[J]. 中草药, 2014, 45(15):2265-2271.
黄永梅.基于网络药理学筛选茯苓萜类抗乙肝病毒活性成分的研究[D]. 宜昌:三峡大学, 2023.
栾娜,钟祥键,王欣,等.山茱萸中具有抗氧化活性的环烯醚萜类成分[J]. 中国食品学报, 2020, 20(11):255-264.
王诗婷,孔伟华,温乐乐,等.中药三萜类成分防治膝骨关节炎作用机制研究进展[J]. 中草药, 2023, 54(18):6128-6138.
卫家润,陈月桥,钟焕英,等.中药萜类成分抗肝纤维化机制研究进展[J]. 辽宁中医药大学学报, 2023,25(9):107-113.
Gan D K, Zhang W, Huang C K, et al. Ursolic acid ameliorates CCl4-induced liver fibrosis through the NOXs/ROS pathway[J]. J Cell Physiol, 2018, 233(10):6799-6813.
Szuster-Ciesielska A, Plewka K, Daniluk J, et al. Betulin and betulinic acid attenuate ethanol-induced liver stellate cell activation by inhibiting reactive oxygen species(ROS), cytokine(TNF-α, TGF-β)production and by influencing intracellular signaling[J]. Toxicology, 2011,280(3):152-163.
Cao F Y, Zhang Y F, Li W G, et al. Mogroside IVE attenuates experimental liver fibrosis in mice and inhibits HSC activation through downregulating TLR4-mediated pathways[J]. Int Immunopharmacol, 2018, 55:183-192.
Mohseni R, Karimi J, Tavilani H, et al. Carvacrol ameliorates the progression of liver fibrosis through targeting of Hippo and TGF-β signaling pathways in carbon tetrachloride(CCl4)-induced liver fibrosis in rats[J]. Immunopharmacol Immunotoxicol, 2019, 41(1):163-171.
Medzhitov R. Origin and physiological roles of inflammation[J]. Nature, 2008, 454(7203):428-435.
马婷,邝晓岚,蔡婉娜,等.黄酮类成分抗肝纤维化作用及其机制的研究进展[J]. 中草药, 2022, 53(13):4146-4161.
Mack M. Inflammation and fibrosis[J]. Matrix Biol, 2018,68:106-121.
Yang L, Bi L P, Jin L L, et al. Geniposide ameliorates liver fibrosis through reducing oxidative stress and inflammatory respose, inhibiting apoptosis and modulating overall metabolism[J]. Front Pharmacol,2021, 12:772635.
Allameh A, Niayesh-Mehr R, Aliarab A, et al. Oxidative stress in liver pathophysiology and disease[J]. Antioxidants, 2023, 12(9):1653.
蔡欣池,崔万丽.肝纤维化发生机制的研究进展[J]. 吉林医药学院学报, 2021, 42(2):141-143.
谢婧,李丽华.脱水穿心莲内酯对四氯化碳诱导的肝纤维化模型小鼠肝细胞凋亡的抑制作用及其机制[J]. 吉林大学学报:医学版, 2019, 45(5):1009-1014.
Li J P, Gao Y, Chu S F, et al. Nrf2 pathway activation contributes to anti-fibrosis effects of ginsenoside Rg1 in a rat model of alcohol-and CCl4-induced hepatic fibrosis[J]. Acta Pharmacol Sin, 2014, 35(8):1031-1044.
Higashi T, Friedman S L, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis[J]. Adv Drug Deliv Rev,2017, 121:27-42.
何国鑫,陈华国,邓青芳,等.黄酮类化合物抗肝损伤的作用机制研究进展[J]. 中国现代应用药学, 2019,36(12):1583-1591.
王莹,徐渴阳,包剑锋.细胞自噬对氧化应激通路的调节及其对肝纤维化的影响[J]. 中国卫生检验杂志,2020, 30(14):1716-1718.
Liu Y M, Cong S, Cheng Z, et al. Platycodin D alleviates liver fibrosis and activation of hepatic stellate cells by regulating JNK/c-Jun signal pathway[J]. Eur J Pharmacol, 2020, 876:172946.
胡宗涛,高世乐,秦峰,等.单次剂量照射制备大鼠放射性肝纤维化模型的建立与评价[J]. 安徽医药, 2013,17(1):63-67.
Yang Z F, Klionsky D J. Eaten alive:A history of macroautophagy[J]. Nat Cell Biol, 2010, 12(9):814-822.
Hung T M, Hsiao C C, Lin C W, et al. Complex cell typespecific roles of autophagy in liver fibrosis and cirrhosis[J]. Pathogens, 2020, 9(3):225.
Lucantoni F, Martínez-Cerezuela A, Gruevska A, et al.Understanding the implication of autophagy in the activation of hepatic stellate cells in liver fibrosis:Are we there yet?[J]. J Pathol, 2021, 254(3):216-228.
田萌媛,张铭,赵哲,等.基于自噬探讨中医药抗肝纤维化的研究进展[J]. 中国实验方剂学杂志, 2023,29(21):255-263.
Chen Y R, Que R Y, Zhang N, et al. Saikosaponin-D alleviates hepatic fibrosis through regulating GPER1/autophagy signaling[J]. Mol Biol Rep, 2021, 48(12):7853-7863.
陈华玲,马晓鹂,袁圣亮.自噬与炎症的关系研究进展[J]. 山东医药, 2016, 56(23):100-102.
Zhang Z L, Guo M, Zhao S F, et al. ROS-JNK1/2-dependent activation of autophagy is required for the induction of anti-inflammatory effect of dihydroartemisinin in liver fibrosis[J]. Free Radic Biol Med, 2016, 101:272-283.
Liu X X, Mi X J, Wang Z, et al. Ginsenoside Rg3 promotes regression from hepatic fibrosis through reducing inflammation-mediated autophagy signaling pathway[J]. Cell Death Dis, 2020, 11(6):454.
王伟艳,刘珊,李会芳,等.基于谷胱甘肽/谷胱甘肽过氧化物酶4轴探讨雷公藤甲素引起肝细胞铁死亡的作用机制[J]. 中草药, 2024, 55(9):2967-2975.
Zhang Y Y, Su F Z, Zhu E L, et al. A systematical review on traditional Chinese medicine treating chronic diseases via regulating ferroptosis from the perspective of experimental evidence and clinical application[J]. Chin Herb Med, 2025, 17(2):246-260.
Zhang Z L, Yao Z, Wang L, et al. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells[J]. Autophagy, 2018, 14(12):2083-2103.
Zheng Y, Zhao T J, Wang J R, et al. Curcumol alleviates liver fibrosis through inducing autophagy and ferroptosis in hepatic stellate cells[J]. FASEB J, 2022, 36(12):e22665.
Lang Z C, Yu S H, Hu Y H, et al. Ginsenoside Rh2promotes hepatic stellate cell ferroptosis and inactivation via regulation of IRF1-inhibited SLC7A11[J]. Phytomedicine, 2023, 118:154950.
Dewidar B, Meyer C, Dooley S, et al. TGF-β in hepatic stellate cell activation and liver fibrogenesis-updated 2019[J]. Cells, 2019, 8(11):1419.
Derynck R, Budi E H. Specificity, versatility, and control of TGF-β family signaling[J]. Sci Signal, 2019, 12(570):eaav5183.
Carthy J M. TGFβ signaling and the control of myofibroblast differentiation:Implications for chronic inflammatory disorders[J]. J Cell Physiol, 2018, 233(1):98-106.
Fabregat I, Caballero-Díaz D. Transforming growth factor-β-induced cell plasticity in liver fibrosis and hepatocarcinogenesis[J]. Front Oncol, 2018, 8:357.
曹杨港,陈月桥,胡锦,等.基于TGF-β1/Smads通路的中医药治疗肝纤维化研究进展[J]. 中西医结合肝病杂志, 2023, 33(7):664-668.
魏晓宇.人参皂苷Rg1通过TGF-β/Samd信号通路抑制肝纤维的机制研究[D]. 重庆:重庆医科大学, 2018.
Guo X X, Yang W N, Dong B S, et al. Glycyrrhetinic acidinduced miR-663a alleviates hepatic stellate cell activation by attenuating the TGF-β/Smad signaling pathway[J]. Evid Based Complement Alternat Med, 2020, 2020:3156267.
Tang L X, He R H, Yang G, et al. Asiatic acid inhibits liver fibrosis by blocking TGF-beta/Smad signaling in vivo and in vitro[J]. PLoS One, 2012, 7(2):e31350.
薛瑾,陈应强. Nrf2/HO-1信号通路在肝脏相关疾病中的研究进展[J]. 南昌大学学报(医学版), 2022, 62(3):88-92.
Zhu L Y, Zhang Q, Hua C, et al. Melatonin alleviates particulate matter-induced liver fibrosis by inhibiting ROS-mediated mitophagy and inflammation via Nrf2activation[J]. Ecotoxicol Environ Saf, 2023, 268:115717.
Bellezza I, Giambanco I, Minelli A, et al. Nrf2-Keap1signaling in oxidative and reductive stress[J]. Biochim Biophys Acta BBA Mol Cell Res, 2018, 1865(5):721-733.
张晓倩,杨慧,张晓华. Nrf2/HO-1信号通路在慢性肝病中的研究[J]. 中国肝脏病杂志(电子版), 2017,9(3):36-39.
杨娟. Nrf2-∕-对AS-Ⅳ经由pSmad3C/3L抗肝纤维化作用机制的影响[D]. 合肥:安徽医科大学, 2022.
段丽杰,王立新.甘草酸二铵对四氯化碳诱导肝纤维化模型小鼠氧化应激损伤的保护作用[J]. 天津药学,2022, 34(1):1-7.
方惠娴,王剑锋,朱向东.中医药干预PI3K/Akt信号通路抗肝纤维的研究进展[J]. 中医临床研究, 2018,10(8):146-148.
Guo M D, Zhu C H, Fu R Z, et al. Ginsenoside Rk3regulates nonalcoholic steatohepatitis by modulation of intestinal flora and the PI3K/Akt signaling pathway in C57BL/6 mice[J]. J Agric Food Chem, 2023, 71(24):9370-9380.
Fruman D A, Chiu H, Hopkins B D, et al. The PI3K pathway in human disease[J]. Cell, 2017, 170(4):605-635.
Mendoza M C, Emrah Er E, Blenis J. The Ras-ERK and PI3K-mTOR pathways:Cross-talk and compensation[J]. Trends Biochem Sci, 2011, 36(6):320-328.
Ward S G, Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents[J]. Curr Opin Pharmacol, 2003, 3(4):426-434.
Yokota J, Chosa N, Sawada S, et al. PDGF-induced PI3Kmediated signaling enhances the TGF-β-induced osteogenic differentiation of human mesenchymal stem cells in a TGF-β-activated MEK-dependent manner[J]. Int J Mol Med, 2014, 33(3):534-542.
杨星,王振,李淑娣,等.基于PI3K/Akt信号通路探讨中药活性成分抗肝纤维化的研究现状[J]. 中国实验方剂学杂志, 2023, 29(13):230-240.
Chen D Q, Feng Y L, Cao G, et al. Natural products as a source for antifibrosis therapy[J]. Trends Pharmacol Sci,2018, 39(11):937-952.
Abraldes J G, Tarantino I, Turnes J, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis[J]. Hepatology, 2003, 37(4):902-908.
郑洋,邓青梅,陈豪,等.基于PI3K/Akt/mTOR信号通路探讨莪术醇抗肝纤维化的分子机制[J]. 中药药理与临床, 2021, 37(4):36-40.
唐菀,赵楠,张晓珣,等.青蒿琥酯通过PI3K/Akt/m TOR信号通路改善DDC诱导的胆汁淤积性肝纤维化[J]. 陆军军医大学学报, 2023, 45(10):1001-1009.
Kim E K, Choi E J. Pathological roles of MAPK signaling pathways in human diseases[J]. Biochim Biophys Acta,2010, 1802(4):396-405.
赖学倩,刘俊宏,王亮,等.中药调控相关信号通路抗肝纤维化的研究进展[J]. 中华中医药学刊, 2023,41(11):215-221.
邓志华,黄桂柳,覃小珊,等. p38 MAPK信号通路与肝脏疾病关系的研究进展[J]. 医学综述, 2020, 26(22):4395-4403.
詹康.肝纤维化发生相关信号传导通路的研究进展[J]. 湖北民族大学学报:医学版, 2020, 37(3):87-90.
张雅.川西獐牙菜中苦龙胆酯苷的提纯及其抗肝纤维化作用机制研究[D]. 西安:中国人民解放军空军军医大学, 2018.
Su G Y, Li Z Y, Wang R, et al. Signaling pathways involved in p38-ERK and inflammatory factors mediated the antifibrosis effect of AD-2 on thioacetamide-induced liver injury in mice[J]. Food Funct, 2019, 10(7):3992-4000.
文皑巍. Toll样受体信号通路在肝纤维化机制中的作用[D]. 重庆:重庆医科大学, 2015.
杨超,谭勤锐,李晖. Toll样受体对肝纤维化的调控作用进展[J]. 重庆医学, 2017, 46(20):2853-2856.
金英顺,洪英礼,崔镇花,等.血管紧张素Ⅱ及其受体在慢性环孢素A肾毒性大鼠肾组织中的表达[J]. 第二军医大学学报, 2010, 31(12):1286-1290.
Lai L N, Chen Y X, Tian X X, et al. Artesunate alleviates hepatic fibrosis induced by multiple pathogenic factors and inflammation through the inhibition of LPS/TLR4/NF-κB signaling pathway in rats[J]. Eur J Pharmacol, 2015, 765:234-241.
Lin L T, Li R, Cai M Y, et al. Andrographolide ameliorates liver fibrosis in mice:Involvement of TLR4/NF-κB and TGF-β1/Smad2 signaling pathways[J]. Oxid Med Cell Longev, 2018, 2018:7808656.
王莉,赵秀萍,谢娇娇,等. Hippo-YAP/TAZ与Notch信号通路在肝纤维化中的作用[J]. 生命的化学, 2023,43(3):402-407.
Zhang Q D, Xu M Y, Cai X B, et al. Myofibroblastic transformation of rat hepatic stellate cells:The role of Notch signaling and epithelial-mesenchymal transition regulation[J]. Eur Rev Med Pharmacol Sci, 2015, 19(21):4130-4138.
Li J J, Dong S Q, Ye M L, et al. microRNA-489-3p represses hepatic stellate cells activation by negatively regulating the JAG1/Notch3 signaling pathway[J]. Dig Dis Sci, 2021, 66(1):143-150.
张望.基于Notch3/NOX4信号通路探究熊果酸抗肝纤维化的分子机制[D]. 南昌:南昌大学, 2023.
Xiao X H, Zhang Q. Asiaticoside conveys an antifibrotic effect by inhibiting activation of hepatic stellate cells via the Jagged-1/Notch-1 pathway[J]. J Nat Med, 2023, 77(1):128-136.
Darnell J E Jr, Kerr I M, Stark G R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins[J]. Science, 1994,264(5164):1415-1421.
Aaronson D S, Horvath C M. A road map for those who don’t know JAK-STAT[J]. Science, 2002, 296(5573):1653-1655.
Kisseleva T, Bhattacharya S, Braunstein J, et al. Signaling through the JAK/STAT pathway, recent advances and future challenges[J]. Gene, 2002, 285(1/2):1-24.
O’Sullivan L A, Liongue C, Lewis R S, et al. Cytokine receptor signaling through the JAK-STAT-SOCS pathway in disease[J]. Mol Immunol, 2007, 44(10):2497-2506.
Murray P J. The JAK-STAT signaling pathway:Input and output integration[J]. J Immunol, 2007, 178(5):2623-2629.
Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation[J]. Nat Rev Immunol,2007, 7(6):454-465.
邓灿,叶波平.肝纤维化发生机制及治疗研究进展[J]. 药物生物技术, 2017, 24(5):454-458.
李明芳,李曹飞,左东泽,等.肝纤维化的发病机理及相关信号转导机制研究进展[J]. 中国比较医学杂志,2023, 33(8):147-152.
Liu J, Wang F P, Luo F M. The role of JAK/STAT pathway in fibrotic diseases:Molecular and cellular mechanisms[J]. Biomolecules, 2023, 13(1):119.
Fan J, Chen Q S, Wei L W, et al. Asiatic acid ameliorates CCl4-induced liver fibrosis in rats:Involvement of Nrf2/ARE, NF-κB/IκBα, and JAK1/STAT3 signaling pathways[J]. Drug Des Devel Ther, 2018, 12:3595-3605.
Zhao H Z, Wu L, Zhang Y, et al. Betulinic acid prevents liver fibrosis by binding Lck and suppressing Lck in HSC activation and proliferation[J]. J Ethnopharmacol, 2022,296:115459.
Zanin-Zhorov A, Blazar B R. ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease[J]. Clin Immunol, 2021, 230:108823.
Shimizu T, Liao J K. Rho kinases and cardiac remodeling[J]. Circ J, 2016, 80(7):1491-1498.
Yu B, Sladojevic N, Blair J E, et al. Targeting Rhoassociated coiled-coil forming protein kinase(ROCK)in cardiovascular fibrosis and stiffening[J]. Expert Opin Ther Targets, 2020, 24(1):47-62.
Nagai Y, Matoba K, Kawanami D, et al. ROCK2 regulates TGF-β-induced expression of CTGF and profibrotic genes via NF-κB and cytoskeleton dynamics in mesangial cells[J]. Am J Physiol Renal Physiol, 2019, 317(4):F839-F851.
郑洋.莪术醇对肝纤维化小鼠肝星状细胞Rho-ROCK信号通路的影响[D]. 南宁:广西中医药大学, 2019.
罗方云. NOX4/ROS和RhoA/ROCK1信号通路在肝纤维化中的作用及熊果酸的干预靶点[D]. 南昌:南昌大学, 2019.
Feng M, Ding J, Wang M, et al. Kupffer-derived matrix metalloproteinase-9 contributes to liver fibrosis resolution[J]. Int J Biol Sci, 2018, 14(9):1033-1040.
Lee H S, Choi J, Son T, et al. Altered AKAP12 expression in portal fibroblasts and liver sinusoids mediates transition from hepatic fibrogenesis to fibrosis resolution[J]. Exp Mol Med, 2018, 50(4):1-13.
Cariello M, Piccinin E, Moschetta A. Transcriptional regulation of metabolic pathways via lipid-sensing nuclear receptors PPARs, FXR, and LXR in NASH[J]. Cell Mol Gastroenterol Hepatol, 2021, 11(5):1519-1539.
Zhang Q H, Xiang S H, Liu Q Q, et al. PPARγ antagonizes hypoxia-induced activation of hepatic stellate cell through cross mediating PI3K/Akt and cGMP/PKG signaling[J]. PPAR Res, 2018, 2018:6970407.
Khanam A, Saleeb P G, Kottilil S. Pathophysiology and treatment options for hepatic fibrosis:Can it be completely cured?[J]. Cells, 2021, 10(5):1097.
Francque S M, Pierre B, Abdelmalek M F, et al. A randomised, double-blind, placebo-controlled, multicentre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis:Design of the NATIVE study[J]. Contemp Clin Trials, 2020, 98:106170.
Chen Y N, Hsu S L, Liao M Y, et al. Ameliorative effect of curcumin-encapsulated hyaluronic acid-PLA nanoparticles on thioacetamide-induced murine hepatic fibrosis[J]. Int J Environ Res Public Health, 2016, 14(1):11.

2026年第57卷第18期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.7501/j.issn.0253-2670.2026.18.004

接收时间：2025-12-15
首发时间：2026-10-29

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2025-12-15

基金

作者信息

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501/j.issn.0253-2670.2026.18.004

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT